Merdury Biopharmaceutical 6932.TWO · TWD

Its shares trade on Taipei Exchange under the ticker 6932.TWO. It has been listed since 23 December 2022. In the fiscal year to 31 December 2024, it reported revenue of TWD 5.0m and a net loss of TWD 50.6m. At that date it held total assets of TWD 353.2m and shareholders' equity of TWD 290.3m.

Mercury Biopharmaceutical Corp. manufactures pharmaceutical products. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-23. The firm mainly focuses on the development of drugs that do not meet special medical needs, difficult generic drugs and second-class new drugs. With the self-developed and multi-national patented drug development platform StackDose, the Company can develop products that can achieve controllable time-dissolving (instant or sustained release) tablets, thereby controlling the time for the drug to take effect. The main products include Sildenafil, Metformin, Tadalafil, Zolpidem, angina drugs, migraine drugs, multi-ingredient antihypertensive drugs and others. The products are mainly sold in Taiwan and the United States.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yu-lung LinChairman of the Board, since 2019
• Mr. Phillip ChangChief Marketing Officer, Director, since 2022
• Yaoren LiangGeneral Manager, Director, since 2019
• Ms. Chun-Chun ChangDeputy General Manager-Administrative Division, Corporate Governance Officer
• Mr. Chaoyi ChenChief Research & Development Officer, since 2023
• Mr. Jui-Hsin ChenDirector
• Fuxiang ChenIndependent Director
• Mr. Qunzhi ChenIndependent Director
• Mr. Ping-Ying ChiangIndependent Director
• Ms. Hsin-Bei ShenIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.